AU2022479909A1 - Sotorasib dosing regimen - Google Patents

Sotorasib dosing regimen Download PDF

Info

Publication number
AU2022479909A1
AU2022479909A1 AU2022479909A AU2022479909A AU2022479909A1 AU 2022479909 A1 AU2022479909 A1 AU 2022479909A1 AU 2022479909 A AU2022479909 A AU 2022479909A AU 2022479909 A AU2022479909 A AU 2022479909A AU 2022479909 A1 AU2022479909 A1 AU 2022479909A1
Authority
AU
Australia
Prior art keywords
cancer
patient
sotorasib
dose
rosuvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022479909A
Other languages
English (en)
Inventor
Panli CARDONA
Brett E. HOUK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2022479909A1 publication Critical patent/AU2022479909A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022479909A 2022-09-30 2022-12-16 Sotorasib dosing regimen Pending AU2022479909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
US63/411,789 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (1)

Publication Number Publication Date
AU2022479909A1 true AU2022479909A1 (en) 2025-02-06

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022479909A Pending AU2022479909A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Country Status (9)

Country Link
US (2) US20260083741A1 (enExample)
EP (1) EP4593837A1 (enExample)
JP (1) JP2025533334A (enExample)
KR (1) KR20250079183A (enExample)
AU (1) AU2022479909A1 (enExample)
JO (1) JOP20250064A1 (enExample)
MX (1) MX2025003741A (enExample)
TW (1) TW202415380A (enExample)
WO (1) WO2024072437A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
WO2024072437A1 (en) 2024-04-04
TW202415380A (zh) 2024-04-16
KR20250079183A (ko) 2025-06-04
MX2025003741A (es) 2025-05-02
US20260166040A1 (en) 2026-06-18
JOP20250064A1 (ar) 2025-03-25
JP2025533334A (ja) 2025-10-06
EP4593837A1 (en) 2025-08-06
US20260083741A1 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
EP1859793B1 (en) Novel combinational use of a sulfonamide compound in the treatment of cancer
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
US20220323446A1 (en) Sotorasib dosing regimen
IL295514A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
US20260069593A1 (en) Methods for treating cancer
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
CN113423402A (zh) 癌症治疗
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
Beumer et al. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short‐bowel syndrome
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20260083741A1 (en) Sotorasib dosing regimen
CA3269092A1 (en) Sotorasib dosing regimen
KR20240009465A (ko) 진행성 고형 종양의 치료를 위한 fgfr 티로신 키나제 억제제
AU2023366820A1 (en) Methods of treating cancer with sotorasib
EA053101B1 (ru) Способы лечения рака с помощью соторасиба
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40013982A (en) Cancer treatment
Sakuma et al. Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines